Mikael S Lindstrom
Overview
Explore the profile of Mikael S Lindstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Espinoza J, Kanellis D, Saproo S, Leal K, Martinez J, Bartek J, et al.
Nucleic Acids Res
. 2024 Feb;
52(8):4151-4166.
PMID: 38340348
In cancer therapy, DNA intercalators are mainly known for their capacity to kill cells by inducing DNA damage. Recently, several DNA intercalators have attracted much interest given their ability to...
2.
Kanellis D, Zisi A, Skrott Z, Lemmens B, Espinoza J, Kosar M, et al.
Cell Death Differ
. 2023 May;
30(7):1666-1678.
PMID: 37142656
Drug repurposing is a versatile strategy to improve current therapies. Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value...
3.
Zisi A, Kanellis D, Moussaud S, Karlsson I, Caren H, Brautigam L, et al.
Neuro Oncol
. 2022 Dec;
25(6):1058-1072.
PMID: 36583853
Background: High-grade gliomas are malignant brain tumors characterized by aggressiveness and resistance to chemotherapy. Prognosis remains dismal, highlighting the need to identify novel molecular dependencies and targets. Ribosome biogenesis (RiBi),...
4.
Zisi A, Bartek J, Lindstrom M
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565259
Rapid growth and unrestrained proliferation is a hallmark of many cancers. To accomplish this, cancer cells re-wire and increase their biosynthetic and metabolic activities, including ribosome biogenesis (RiBi), a complex,...
5.
Lindstrom M, Bartek J, Maya-Mendoza A
Cell Death Differ
. 2022 Apr;
29(5):972-982.
PMID: 35444234
Despite several decades of intense research focused on understanding function(s) and disease-associated malfunction of p53, there is no sign of any "mid-life crisis" in this rapidly advancing area of biomedicine....
6.
Kanellis D, Espinoza J, Zisi A, Sakkas E, Bartkova J, Katsori A, et al.
Sci Adv
. 2021 Aug;
7(32).
PMID: 34348895
Eukaryotic initiation factor 4A-III (eIF4A3), a core helicase component of the exon junction complex, is essential for splicing, mRNA trafficking, and nonsense-mediated decay processes emerging as targets in cancer therapy....
7.
Correction to: SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma
Guo M, Goudarzi K, Abedi S, Pieber M, Sjoberg E, Behnan J, et al.
Oncogene
. 2021 Jul;
40(32):5153.
PMID: 34257430
No abstract available.
8.
Guo M, Goudarzi K, Abedi S, Pieber M, Sjoberg E, Behnan J, et al.
Oncogene
. 2021 May;
40(32):5066-5080.
PMID: 34021259
Intratumoral heterogeneity is a characteristic of glioblastomas that contain an intermixture of cell populations displaying different glioblastoma subtype gene expression signatures. Proportions of these populations change during tumor evolution, but...
9.
Guo M, van Vliet M, Zhao J, Diaz De Stahl T, Lindstrom M, Cheng H, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdaa061.
PMID: 32642713
Background: Glioblastomas display a high level of intratumoral heterogeneity with regard to both genetic and histological features. Within single tumors, subclones have been shown to communicate with each other to...
10.
Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, et al.
Cancer Res
. 2020 Feb;
80(7):1538-1550.
PMID: 32019870
Identification of the molecular mechanism of action (MoA) of bioactive compounds is a crucial step for drug development but remains a challenging task despite recent advances in technology. In this...